Live, Attenuated Mumps-Virus Vaccine

Abstract

PREVIOUS reports^{1 2 3 4} described the development of the Jeryl Lynn B level live, attenuated mumps-virus vaccine, the findings in early clinical tests of the vaccine and the serologic and clinical responses to the vaccine in a controlled field study carried out in the Havertown–Springfield suburb of Philadelphia during the fall, winter and spring of 1965–66. The present report summarizes the data on the protective efficacy of the vaccine against natural mumps challenge in the Havertown–Springfield study.ResultsConduct of the StudyDetails of the study plan were previously described,³ and only the essential aspects are given here. Lot 137 of Jeryl . . .